Bayesian meta‐analysis of phase 3 results of aducanumab, lecanemab, donanemab, and high‐dose gantenerumab in prodromal and mild Alzheimer's disease

Documenti analoghi

• Clinical efficacy of anti‐amyloid antibodies in apolipoprotein E ε4 homozygotes: A Bayesian reanalysis of lecanemab and donanemab phase 3 results
  di: Stefan Teipel, et al.
  Pubblicazione: (2025)
• Infusion‐related reactions in donanemab‐treated participants with early symptomatic Alzheimer's disease
  di: Paul Ardayfio, et al.
  Pubblicazione: (2026)
• Pharmacokinetic/pharmacodynamic analyses of plasma pathophysiology biomarkers in subjects with early Alzheimer's disease following lecanemab treatment
  di: Pratik Bhagunde, et al.
  Pubblicazione: (2026)
• Blood DNA methylation signature of cognitive reserve moderates the association between CSF tau pathology and memory in prodromal Alzheimer's disease
  di: David Lukacsovich, et al.
  Pubblicazione: (2026)
• Clinically meaningful benefit and real‐world evidence in Alzheimer's disease research and care
  di: Robert Perneczky, et al.
  Pubblicazione: (2025)